Ricardo Grieshaber-Bouyer joined Sofinnova as Venture Partner, where he focuses on providing scientific, clinical and technical advice as well as contributing to company formation initiatives.
Ricardo joined Sofinnova in 2026 alongside his academic work at FAU Erlangen-Nürnberg. He has led translational research programs spanning first-in-human clinical trials, single-cell immune profiling and computational immunology, and his clinical programs have evaluated more than 15 cell-depleting therapies across more than ten autoimmune diseases. His team led the first-in-human applications of T cell engagers in autoimmune disease, and he has served as Global Principal Investigator for several early-stage clinical trials of cell-depleting therapies. His work has been published in The New England Journal of Medicine, Nature Medicine and The Lancet and recognized with the Carol Nachman Junior Research Prize, and his research has been funded by the European Research Council (ERC) and the German Research Foundation (DFG). For his contributions at the interface of academic medicine, science and biotech, he was named to Forbes 30 Under 30 in Science and Healthcare.
Ricardo received his MD from Heidelberg University, where he also completed a research doctorate in immunology (Dr. med., summa cum laude), conducted largely at Brigham and Women’s Hospital, Harvard Medical School, where he went on to train as a postdoctoral fellow with the ImmGen Consortium. He holds a Master of Health Business Administration (MHBA) from FAU Erlangen-Nürnberg and is board certified in internal medicine, rheumatology and immunology.